{Reference Type}: Journal Article
{Title}: High baseline fetuin-A levels are associated with lower atherosclerotic plaque progression as measured by 3D ultrasound.
{Author}: Sommer P;Schreinlechner M;Noflatscher M;Lener D;Mair F;Theurl M;Kirchmair R;Marschang P;
{Journal}: Atheroscler Plus
{Volume}: 45
{Issue}: 0
{Year}: Nov 2021
暂无{DOI}: 10.1016/j.athplu.2021.09.001
{Abstract}: <B>UNASSIGNED: </B>The glycoprotein fetuin-A has anti-inflammatory effects, increases insulin resistance and plays an important role in calcium metabolism. The aim of our study was to assess the predictive value of fetuin-A on atherosclerotic plaque progression in comparison to the established cardiovascular biomarker high sensitivity C-reactive protein (hsCRP).<BR><B>UNASSIGNED: </B>In this prospective, single center-, cohort study, we included 194 patients with at least one cardiovascular risk factor or established cardiovascular disease (CVD). Over a period of 4 years, each patient underwent 3D plaque volumetry of the carotid and femoral arteries on a yearly basis. To evaluate the predictive value of biomarkers in terms of plaque progression, the baseline values of fetuin-A and hsCRP were correlated with the plaque progression from baseline to the last follow up visit.<BR><B>UNASSIGNED: </B>171 patients were included in the final analysis. Baseline fetuin-A levels showed a significant negative correlation with plaque progression (r = -0.244; p = 0.001). In contrast, baseline hsCRP levels showed no correlation with plaque progression (r = 0.096, p = 0.20). In the ROC-analysis, fetuin-A had a significantly better predictive value than hsCRP (fetuin-A AUC 0.67; p = 0.001 vs hsCRP AUC 0.49; p = 0.88) with an optimal cut-off value at 712 μg/ml. In patients with high fetuin A levels (>712 μg/ml), a significantly lower plaque progression was observed compared to the group with low fetuin-A levels <712 μg/ml (high fetuin-A 197 mm3 vs. low fetuin-A 279 mm3; p = 0.01).<BR><B>UNASSIGNED: </B>Higher fetuin-A levels appear to predict lower atherosclerotic plaque progression in patients with or at risk of cardiovascular disease.